Competitive Market Outcome

The trial success supports eventual approval, but the drug enters a more crowded kidney-disease market after recent advances from Travere and Vera. Uptake depends on label breadth, dosing convenience, payer controls and whether physicians view the Roche-Ionis mechanism as complementary or directly substitutive.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.